AL-ADTRAN
17.5.2022 11:32:12 CEST | Business Wire | Press release
Adtran, Inc. , (NASDAQ: ADTN), the leading provider of next-generation multi-gigabit fiber access and fiber extension solutions, today announced Fibernet is leveraging the Adtran 10G Fiber Access Platform to build an XGS-PON fiber network that will connect 50,000 customers in its first phase. Fibernet is leveraging its innovative fiber trenching technology to quickly build a fiber network and is using Adtran’s reliable 10G solutions to deploy competitive, scalable broadband services to households and businesses in Finland.
Fibernet is a new alternative network provider (altnet) in Finland, where much of the country can access 4G mobile broadband coverage. However, increased demand for high-bandwidth, reliable internet means that fiber connections are a necessity. While some established service providers began slowly building expensive fiber networks, Fibernet invested in an innovative fiber trenching approach that allows the altnet to build its network much faster. Fibernet selected the Adtran 10G Fiber Access Platform as its foundation to launch high-quality, competitive broadband services for internet, IPTV, telehealth and more.
“While Fibernet is new to this market, our leaders have deep experience in implementing superior broadband networks. We selected Adtran because of its experience in both the fiber access and altnet markets, and together we make a great team. We are extremely pleased with the support that Adtran has provided in our startup phase,” said Janne Ahola, CEO at Fibernet. “We understand that fiber is the only way to supply fast and reliable network connections that can scale with subscriber demands. Adtran provides a solution that can help us meet those needs today and in the future.”
The Adtran 10G Fiber Access Platform leverages the symmetrical upload and download speeds of XGS-PON technology, which future-proofs the network against growing demand for high-bandwidth cloud and streaming services. Adtran’s supply availability is also a differentiator for Fibernet. In Finland, the ground is frozen for five months each year. The long winters require well-planned building seasons and hardware deliveries must be on schedule during the warmer months. Adtran offers a comprehensive end-to-end access portfolio that allows Fibernet to order most of the hardware from a single vendor to better ensure on-time deliveries.
“Fibernet has a key advantage with its micro-trenching technology that lets it build its fiber network much faster. With Adtran in its network, Fibernet can match that innovation with a 10G fiber access platform that will provide reliable, high-quality services today and grow with them as subscriber demands evolve,” said Stuart Broome, Vice President of Sales, EMEA at Adtran. “The ease of scalability will enable Fibernet to increase capacity and scale services beyond its traditional residential subscriber base to support the connectivity needs of local small- and mid-sized businesses as well.”
For more information about the Adtran 10G Fiber Access Platform , visit www.adtran.com/fiber-access .
About Adtran
Adtran, Inc. is a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are currently in use by service providers, private enterprises, government organizations and millions of individual users worldwide. Find more at Adtran , LinkedIn and Twitter .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220517005203/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release
SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
